Drugs / PV-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07081334 | Aug 2022 → Apr 2024 | human papilloma virus infection | POSVAX | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PV-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07081334 ↗ |
| Modality | Vaccine | “PV-001, a 9-valent human papillomavirus (HPV) vaccine candidate manufactured in Saccharomyces cerevisiae” PMID 41048471 ↗ Sep 2025 |
| Route | Intramuscular | “administered the assigned intervention via intramuscular injection at 0, 2, and 6 months.” PMID 41048471 ↗ Sep 2025 |